Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Successful treatment with Remdesivir and corticosteroids in a patient with COVID-19-associated pneumonia : A case report

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread throughout the world causing significant mortality in high risk patients with severe manifestations. To date, Remdesivir has been the only antiviral authorized by FDA as therapy for emergency use. One of the potential complications of this infection is cytokine storm, which optimal treatment remains unknown. We present the case of a 48-year-old man with no past medical history who presented to the hospital with dyspnea, cough, subjective fever, and diarrhea for 10 days. Nasopharyngeal PCR was positive for SARS-CoV-2. His respiratory status rapidly worsened to the point of requiring supplemental oxygen by high flow nasal cannula with FiO2 of 80%. Chest computed tomography showed confluent ground glass opacities in upper lobes accompanied by patchy airspace opacities in lower lobes bilaterally. He was started on hydroxychloroquine, which was switched to Remdesivir when it became available. Then, methylprednisolone was initiated for suspected cytokine storm. The patients oxygenation improved significantly over the following days and he was discharged home with no oxygen supplementation and saturating 96% on room air. Our case illustrates the role of Remdesivir for the treatment of severe COVID-19 pneumonia. We also observed a possible clinical benefit of corticosteroids in the context of suspected cytokine storm. Further studies are needed to evaluate this therapeutic strategy

Year of Publication: 2020
Contained in: Medwave Vol. 20, No. 7 (2020), p. e7998
All journal articles: Search for all articles in this journal
Language: Spanish
Contributors: Gonzales-Zamora, José A | Author
Quiroz, Tanya
Vega, Ana D
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: 3QKI37EEHE
415SHH325A
Case Reports
OF5P57N2ZX
X4W7ZR7023
coronavirus
methylprednisolone
remdesivir
steroids
Additional Keywords: *Betacoronavirus
Adenosine Monophosphate
Alanine
Antiviral Agents
Coronavirus Infections
Cytokine Release Syndrome
Glucocorticoids
Humans
Male
Methylprednisolone
Middle Aged
Pandemics
Pneumonia, Viral
ISSN: 0717-6384
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 09.09.2020
Date Revised 09.09.2020
published: Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32876623
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.5867/medwave.2020.07.7998
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 04747nma a2200901 c 4500
001 NLM31544133X
003 DE-601
005 20200911214507.0
007 cr uuu---uuuuu
008 200902s2020 000 0 spa d
024 7 |a 10.5867/medwave.2020.07.7998  |2 doi 
028 5 2 |a pubmed20n1335.xml 
035 |a (DE-599)NLM32876623 
040 |b ger  |c GBVCP 
041 0 |a spa 
100 1 |a Gonzales-Zamora, José A 
245 1 0 |a Successful treatment with Remdesivir and corticosteroids in a patient with COVID-19-associated pneumonia  |h Elektronische Ressource  |b A case report 
246 3 |a Tratamiento exitoso con Remdesivir y corticoides en un paciente con neumonía asociada a COVID-19: reporte de un caso 
300 |a Online-Ressource 
500 |a Date Completed 09.09.2020 
500 |a Date Revised 09.09.2020 
500 |a published: Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread throughout the world causing significant mortality in high risk patients with severe manifestations. To date, Remdesivir has been the only antiviral authorized by FDA as therapy for emergency use. One of the potential complications of this infection is cytokine storm, which optimal treatment remains unknown. We present the case of a 48-year-old man with no past medical history who presented to the hospital with dyspnea, cough, subjective fever, and diarrhea for 10 days. Nasopharyngeal PCR was positive for SARS-CoV-2. His respiratory status rapidly worsened to the point of requiring supplemental oxygen by high flow nasal cannula with FiO2 of 80%. Chest computed tomography showed confluent ground glass opacities in upper lobes accompanied by patchy airspace opacities in lower lobes bilaterally. He was started on hydroxychloroquine, which was switched to Remdesivir when it became available. Then, methylprednisolone was initiated for suspected cytokine storm. The patients oxygenation improved significantly over the following days and he was discharged home with no oxygen supplementation and saturating 96% on room air. Our case illustrates the role of Remdesivir for the treatment of severe COVID-19 pneumonia. We also observed a possible clinical benefit of corticosteroids in the context of suspected cytokine storm. Further studies are needed to evaluate this therapeutic strategy 
611 2 7 |a Case Reports  |2 gnd 
653 2 |a Adenosine Monophosphate  |6 D000249  |a *analogs & derivatives  |6 Q000031  |a therapeutic use  |6 Q000627 
653 2 |a Alanine  |6 D000409  |a *analogs & derivatives  |6 Q000031  |a therapeutic use  |6 Q000627 
653 2 |a Antiviral Agents  |6 D000998  |a *therapeutic use  |6 Q000627 
653 2 |a *Betacoronavirus  |6 D000073640 
653 2 |a Coronavirus Infections  |6 D018352  |a complications  |6 Q000150  |a diagnosis  |6 Q000175  |a *drug therapy  |6 Q000188 
653 2 |a Cytokine Release Syndrome  |6 D000080424  |a drug therapy  |6 Q000188  |a etiology  |6 Q000209 
653 2 |a Glucocorticoids  |6 D005938  |a therapeutic use  |6 Q000627 
653 2 |a Humans  |6 D006801 
653 2 |a Male  |6 D008297 
653 2 |a Methylprednisolone  |6 D008775  |a therapeutic use  |6 Q000627 
653 2 |a Middle Aged  |6 D008875 
653 2 |a Pandemics  |6 D058873 
653 2 |a Pneumonia, Viral  |6 D011024  |a complications  |6 Q000150  |a diagnosis  |6 Q000175  |a *drug therapy  |6 Q000188 
655 7 |a methylprednisolone  |2 gnd 
655 7 |a remdesivir  |2 gnd 
655 7 |a steroids  |2 gnd 
655 7 |a coronavirus  |2 gnd 
655 7 |a Antiviral Agents  |2 gnd 
655 7 |a Glucocorticoids  |2 gnd 
655 7 |a remdesivir  |2 gnd 
655 7 |a 3QKI37EEHE  |2 gnd 
655 7 |a Adenosine Monophosphate  |2 gnd 
655 7 |a 415SHH325A  |2 gnd 
655 7 |a Alanine  |2 gnd 
655 7 |a OF5P57N2ZX  |2 gnd 
655 7 |a Methylprednisolone  |2 gnd 
655 7 |a X4W7ZR7023  |2 gnd 
689 0 0 |A f  |a Case Reports 
689 0 |5 DE-601 
689 1 0 |a methylprednisolone 
689 1 1 |a remdesivir 
689 1 2 |a steroids 
689 1 3 |a coronavirus 
689 1 |5 DE-601 
689 2 0 |a Antiviral Agents 
689 2 1 |a Glucocorticoids 
689 2 2 |a remdesivir 
689 2 3 |A r  |a 3QKI37EEHE 
689 2 4 |a Adenosine Monophosphate 
689 2 5 |A r  |a 415SHH325A 
689 2 6 |a Alanine 
689 2 7 |A r  |a OF5P57N2ZX 
689 2 8 |a Methylprednisolone 
689 2 9 |A r  |a X4W7ZR7023 
689 2 |5 DE-601 
700 1 |a Quiroz, Tanya 
700 1 |a Vega, Ana D 
773 0 8 |i in  |t Medwave  |g Vol. 20, No. 7 (2020), p. e7998  |q 20:7<e7998  |w (DE-601)NLM241562090  |x 0717-6384 
856 4 1 |u http://dx.doi.org/10.5867/medwave.2020.07.7998  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 20  |j 2020  |e 7  |b 19  |c 08  |h e7998